Trevyent FDA Approval Status
Last updated by Judith Stewart, BPharm on May 2, 2020.
FDA Approved: No
Brand name: Trevyent
Generic name: treprostinil
Company: United Therapeutics Corporation
Treatment for: Pulmonary Arterial Hypertension
Trevyent (treprostinil) is a preservative-free, parenteral formulation of the approved vasodilatory prostacyclin analogue treprostinil delivered via the proprietary PatchPump infusion system for the treatment of pulmonary arterial hypertension (PAH).
Development timeline for Trevyent
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
